3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Polycystic Ovary Syndrome
5
Neoplasms
3
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Posterior Fossa Ependymal Tumor
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms by Site
1
Metabolic Diseases
1
Insulin Resistance
1
Infertility
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Drug-drug Interaction,SHR3680
1
Diabetes Mellitus, Type 2
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Breast Diseases
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
Cisplatin
6
pembrolizumab
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Fulvestrant
3
palbociclib
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiation Dose Hypofractionation
2
Radiation
2
Platinum
2
Paclitaxel
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Congresses as Topic
2
Carboplatin
2
Brachytherapy
2
Biopsy
2
Bevacizumab
2
Axitinib
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
1,2-diaminocyclohexaneplatinum II citrate
2
zimberelimab
1
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tisotumab vedotin
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Metformin
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled